The Global Ribonucleic Acid (RNA) Markers Market is estimated to be valued at US$ 226.6 Mn or in 2023 and is expected to exhibit a CAGR of 8.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Ribonucleic acid (RNA) markers can quantify both non-coding and messenger RNAs to evaluate changes in gene, cellular and tissue activity or phenotype. They help in improving diagnostic, prognostic and therapeutic applications in various diseases including cancer.
Market key trends:
One of the key trends in the RNA markers market is the increasing adoption of advanced biomarker screening methods and development of new transcriptomic assays. With advancements in sequencing technologies, novel multi-omic approaches have been developed which profile both the genome and transcriptome of a disease specimen. This has enabled comprehensive profiling of disease status along with identification of new biomarkers and drug targets. For instance, CancerSEEK test which combines circulating tumor DNA and protein analysis can detect multiple cancer types from blood sample alone. Such multi-omics based assays are expected to drive the RNA markers market during the forecast period.
Segment Analysis:
One of the key trends in the ribonucleic acid (RNA) markers market is the growing focus on developing liquid biopsy tests using RNA markers. Liquid biopsies analyze fragments of DNA, RNA or proteins found in blood or other bodily fluids to detect cancer early or monitor its progression and response to treatment. Compared to traditional tissue biopsies, liquid biopsies are less invasive procedures and thus help in frequent monitoring of cancer. Several companies are developing liquid biopsy tests that analyze RNA markers in blood or other body fluids to detect disease recurrence or progression. This trend is expected to significantly drive the demand for RNA markers in the coming years.
SWOT Analysis
Strength: Growing applications in oncology for early cancer detection and monitoring treatment response.
Weakness: High cost of development and commercialization of RNA-based tests.
Opportunity: Growing liquid biopsy market and emphasis on minimally invasive cancer screening and diagnosis.
Threats: Intense competition amongst market players and need for extensive clinical validation of RNA marker based tests.
Key Takeaways
The Ribonucleic Acid (Rna) Markers Market Analysis was valued at US$ 226.6 Mn in 2023 and is expected to reach US$ 440.2 Mn by 2030, expanding at a CAGR of 8.7% during the forecast period. The growing focus on developing non-invasive early cancer diagnostics is expected to drive market growth.
Regional analysis
North America currently dominates the RNA markers market due to the strong presence of leading biotech and pharma companies and availability of research funding. Asia Pacific is projected to witness the fastest growth over the forecast period supported by increasing healthcare investments, expanding biotech industry and growing cancer burden in the region.
Key players
Key players operating in the ribonucleic acid (RNA) markers market include Agilent Technologies, Inc., Oxford Gene Technology IP Limited, PerkinElmer Inc., Eurofins Scientific, F. Hoffmann-La Roche Ltd, NextGen Life Sciences Private Limited, bioMérieux SA, New England Biolabs, Promega Corporation, Merck KGaA, Takara Bio Inc., Abnova Corporation, Thermo Fisher Scientific Inc., QIAGEN, Bio-Rad Laboratories, Inc., Lonza, CardioNet, ZOLL Medical Corporation and Hill-Rom Services, Inc.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
